Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vericel Corp (VCEL)
NASDAQ:VCEL
Holding VCEL?
Track your performance easily
VCEL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$30.18 - $53.05
Previous Close$48.5
Volume290.13K
Average Volume (3M)371.76K
Market Cap
$2.36B
Enterprise Value$2.34B
Total Cash (Recent Filing)$109.57M
Total Debt (Recent Filing)$88.04M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Jul 31, 2024EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding48,601,736
10 Day Avg. Volume560,147
30 Day Avg. Volume371,765
Standard Deviation0.16
R-Squared0.32
Alpha0.00959
Financial Highlights & Ratios
Price to Book (P/B)9.68
Price to Sales (P/S)33.65
Price to Cash Flow (P/CF)54.20
P/FCF Ratio228.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.83
Enterprise Value/Gross Profit17.23
Enterprise Value/Ebitda-263.32
Forecast
1Y Price Target
$55.00Price Target Upside10.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Vericel News
PremiumCompany Announcements
Vericel Corporation Reports Strong Q3 2024 Results
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAnalyst recommends a Buy rating for VCEL with a price target increase to $49 based on strong profitability targets and revenue estimates.
Market ConfidenceDeclining short interest in VCEL, now around 5% of the float, contributes to a favorable environment for stock price appreciation.
Product LaunchNew MACI product to increase the current target surgeon population by an additional 2,000, providing a significant growth opportunity.
Bears Say
Acquisition IssuesThe BVS transaction fell apart in mid-2023, allowing SNN to step in and acquire the asset.
Market Size ConcernOsteochondral defects – the type of defects that extend into the subchondral bone – account for about 5% of all articular cartilage lesions.
Product LimitationsA study suggests that osteochondral lesions, which Agili-C is designed to treat, may not be suitable for a fixed osteochondral plug, indicating limitations in the product's applicability.
---
Ownership Overview
5.56% Insiders
34.02% Mutual Funds
23.21% Other Institutional Investors
37.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VCEL FAQ
What was Vericel Corp’s price range in the past 12 months?
Vericel Corp lowest stock price was $30.18 and its highest was $53.05 in the past 12 months.
What is Vericel Corp’s market cap?
Currently, no data Available
When is Vericel Corp’s upcoming earnings report date?
Vericel Corp’s upcoming earnings report date is Jul 31, 2024 which is 112 days ago.
How were Vericel Corp’s earnings last quarter?
Vericel Corp released its earnings results on May 08, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.11 by $0.03.
Is Vericel Corp overvalued?
According to Wall Street analysts Vericel Corp’s price is currently Undervalued.
Does Vericel Corp pay dividends?
Vericel Corp does not currently pay dividends.
What is Vericel Corp’s EPS estimate?
Vericel Corp’s EPS estimate is -$0.09.
How many shares outstanding does Vericel Corp have?
Vericel Corp has 48,601,734 shares outstanding.
What happened to Vericel Corp’s price movement after its last earnings report?
Vericel Corp reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.11. Following the earnings report the stock price went down -3.695%.
Which hedge fund is a major shareholder of Vericel Corp?
Among the largest hedge funds holding Vericel Corp’s share is Fisher Asset Management LLC. It holds Vericel Corp’s shares valued at 8M.
---
Vericel Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.00 (10.33% Upside)
$55.00 (10.33% Upside)
Blogger Sentiment
Bullish
VCEL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 871.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.6%
Last 30 Days ▲ 28.1%
Last 30 Days ▲ 28.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.36%
12-Months-Change
Fundamentals
Return on Equity
0.21%
Trailing 12-Months
Asset Growth
34.54%
Trailing 12-Months
Company Description
Vericel Corp
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
---
VCEL Company Deck
---
VCEL Earnings Call
Q1 2024
0:00 / 0:00
---
VCEL Stock 12 Month Forecast
Average Price Target
$55.00
▲(10.33% Upside)
Technical Analysis
Best Analysts Covering VCEL
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+19.78%
reiterated a buy rating 7 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +19.78% per trade.
---